On April 18, 2024 Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell therapy and genetic medicines company advancing a new class of treatments for patients with cancer and rare diseases, reported that six data presentations highlighting the Company’s preclinical gene therapy programs and platforms will be presented at the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 27th Annual Meeting, being held in Baltimore, MD and virtually on May 7-11, 2024 (Press release, Poseida Therapeutics, APR 18, 2024, View Source [SID1234642159]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the Company’s recent R&D Day held on April 17, 2024, Poseida is focused on advancing fully non-viral genetic medicines employing differentiated gene delivery, editing and insertion technology in addition to its ongoing non-viral allogeneic CAR T programs. The Company’s presentations at ASGCT (Free ASGCT Whitepaper) will feature data on its lead genetic medicine programs P-KLKB1-101 for Hereditary Angioedema (HAE) (gene editing), and P-FVIII-101 for Hemophilia A (non-viral, whole gene insertion).

Oral Presentations:

Title: Highly Specific Non-Viral Gene Editing with P-KLKB1-101 for Hereditary Angioedema
Presenting Author: Blair Madison, Ph.D., Poseida Therapeutics
Session Title: Correction of Genetic Disorders of the Blood and Immune System
Presentation Date/Time: Thursday May 9, 2024, 1:30 – 1:45 PM ET
Location: Room 314-317
Abstract Number: 170

Title: Sustained FVIII Expression with a Tolerable, Titratable, Fully Non-Viral Gene Therapy for Hemophilia A
Presenting Author: Brian Truong, Ph.D., Poseida Therapeutics
Session Title: Liver Genetic Diseases
Presentation Date/Time: Thursday May 9, 2024, 5:00 – 5:15 PM ET
Location: Room 324-326
Abstract Number: 210

Title: A Durable Gene Therapy with a Robust AAV-LNP Delivery System Allowing for a Reduced AAV Dose
Presenting Author: Jack Rychak, Ph.D., Poseida Therapeutics
Session Title: AAV Vectors – Preclinical and Proof-of-Concept: Technology Focus
Presentation Date/Time: Friday May 10, 2024, 1:45 – 2:00 PM ET
Location: Ballroom 2
Abstract Number: 248

Poster Presentations:

Title: Advanced Gene Editing with an Enhanced Site-Specific Nuclease for Knock-Out and Knock-In Applications
Presenting Author: Oscar Alvarez, Ph.D., Poseida Therapeutics
Session Title: Wednesday Posters: Gene Targeting and Gene Correction New Technologies
Session Date/Time: Wednesday, May 8, 2024, 12:00 PM ET
Location: Exhibit Hall
Abstract Number: 717

Title: Optimizing Lipid Nanoparticle Formulations for Enhanced Non-Viral Gene Therapy: Overcoming DNA Delivery Challenges and Achieving High-Efficiency Transgene Integration
Presenting Author: George Wang, Ph.D., Poseida Therapeutics
Session Title: Thursday Posters: Other Nonviral Delivery
Session Date/Time: Thursday, May 9, 2024, 12:00 PM ET
Location: Exhibit Hall
Abstract Number: 1239

Title: Novel Biodegradable Lipid Nanoparticles (LNP) for Co-Encapsulation of Complex Nucleic Acid Payloads for In Vivo Genome Editing
Presenting Author: Alicia Davis, Ph.D., Poseida Therapeutics
Session Title: Friday Posters: Other Nonviral Delivery
Session Date/Time: Friday, May 10, 2024, 12:00 PM ET
Location: Exhibit Hall
Abstract Number: 1737

Accepted abstracts will be available on the ASGCT (Free ASGCT Whitepaper) Annual Meeting website on April 22, 2024 at 4:30 PM ET. Presentations will be available on the Scientific Publications page of Poseida’s website on Friday, May 10, 2024 at 6:00 AM ET.